An FDA advisory committee on Thursday said the confirmatory trial data for the KRAS inhibitor sotorasib (Lumakras) in previously treated non-small cell lung cancer (NSCLC) cannot be reliably ...
The U.S. FDA’s Oncologic Drugs Advisory Committee (ODAC) is taking up the matter of Lumakras (sotorasib), Amgen Inc.’s KRAS-G12C inhibitor that was granted accelerated approval in May 2021 for locally ...
Jun. 04, 2023 8:00 AM ET Amgen Inc. (AMGN) LUMAKRAS ® (sotorasib) Demonstrated Delayed Time to CNS Progression, Longer CNS PFS and Higher Intracranial ORR vs Docetaxel in Post-Hoc Analysis of Phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback